Table 3. Results of the Univariate... | American Society of Hematology

Table 3.

Results of the Univariate Analysis for the 1-Year Transplant-Related Mortality and the 5-Year Overall Survival

Characteristics	No. Studied	No. of Deaths	1-yr TransplantRelated Mortality (%)	P Value	No. of Deaths	5-yr Overall Survival (%)	P Value
Entire group	55	15	27		25	47
Hemoglobin level at diagnosis (g/L)
≤100	17	7	41	.06	8	52	.55
>100	33	6	18		13	48
Age at transplant
<42 yr	29	8	28	.96	13	53	.93
≥42 yr	26	7	27		12	38
Time from diagnosis to transplant
<2 yr	31	8	26	.82	11	59	.17
≥2 yr	24	7	29		14	30
Splenectomy before transplant
Yes	27	8	30	.66	12	48	.92
No	28	7	25		13	46
RBC transfusions before transplant
No	18	1	6	.009	4	70	.009
Yes	36	14	39		21	35
<10 RBC transfusions	30	5	17	.044	10	58	.029
≥10 RBC transfusions	22	9	41		14	31
Hemoglobin level at transplant (g/L)
Hb >100	20	1	5	.005	2	81	.0001
Hb ≤100	35	14	40		23	30
Hemoglobin level at transplant and RBC units before transplant
Hb >100 g/L or Hb ≤100 g/L without transfusion	27	2	8	.0009	5	76	.00008
Hb ≤100 g/L with transfusions required	28	13	46		20	23
Leukocyte count at transplant (10⁹/L)
<4	22	10	46	.017	13	38	.08
≥4	33	5	15		12	53
<4 or >30	30	12	40	.026	16	42	.2
4-30	25	3	12		9	54
Peripheral blood blasts at transplant
Yes	17	5	29	.96	7	59	.72
No	30	9	30		15	56
Dupriez score at transplant
Low-risk score	13	1	8	.005	2	83	.018
Intermediate-risk score	21	3	14		9	43
High-risk score	21	11	53		14	31
Grade III marrow fibrosis (osteomyelosclerosis)
Yes	27	11	41	.023	16	38	.027
No	28	4	14		9	55
Cytogenetic abnormalities before transplant
Yes	13	3	24	.63	7	27	.37
No	32	8	25		12	60
Failure or not available	10	4	40		6	32
Irradiation during the conditioning regimen
Yes	35	11	32	.31	19	41	.15
No	20	4	20		6	59
Grade III-IV acute GVHD
Yes	14	7	51	.035	11	21	.004
No	41	8	20		14	56
Extensive chronic GVHD
Yes	16	3	19	.41	9	35	.05
No	30	3	10		7	69

Characteristics	No. Studied	No. of Deaths	1-yr TransplantRelated Mortality (%)	P Value	No. of Deaths	5-yr Overall Survival (%)	P Value
Entire group	55	15	27		25	47
Hemoglobin level at diagnosis (g/L)
≤100	17	7	41	.06	8	52	.55
>100	33	6	18		13	48
Age at transplant
<42 yr	29	8	28	.96	13	53	.93
≥42 yr	26	7	27		12	38
Time from diagnosis to transplant
<2 yr	31	8	26	.82	11	59	.17
≥2 yr	24	7	29		14	30
Splenectomy before transplant
Yes	27	8	30	.66	12	48	.92
No	28	7	25		13	46
RBC transfusions before transplant
No	18	1	6	.009	4	70	.009
Yes	36	14	39		21	35
<10 RBC transfusions	30	5	17	.044	10	58	.029
≥10 RBC transfusions	22	9	41		14	31
Hemoglobin level at transplant (g/L)
Hb >100	20	1	5	.005	2	81	.0001
Hb ≤100	35	14	40		23	30
Hemoglobin level at transplant and RBC units before transplant
Hb >100 g/L or Hb ≤100 g/L without transfusion	27	2	8	.0009	5	76	.00008
Hb ≤100 g/L with transfusions required	28	13	46		20	23
Leukocyte count at transplant (10⁹/L)
<4	22	10	46	.017	13	38	.08
≥4	33	5	15		12	53
<4 or >30	30	12	40	.026	16	42	.2
4-30	25	3	12		9	54
Peripheral blood blasts at transplant
Yes	17	5	29	.96	7	59	.72
No	30	9	30		15	56
Dupriez score at transplant
Low-risk score	13	1	8	.005	2	83	.018
Intermediate-risk score	21	3	14		9	43
High-risk score	21	11	53		14	31
Grade III marrow fibrosis (osteomyelosclerosis)
Yes	27	11	41	.023	16	38	.027
No	28	4	14		9	55
Cytogenetic abnormalities before transplant
Yes	13	3	24	.63	7	27	.37
No	32	8	25		12	60
Failure or not available	10	4	40		6	32
Irradiation during the conditioning regimen
Yes	35	11	32	.31	19	41	.15
No	20	4	20		6	59
Grade III-IV acute GVHD
Yes	14	7	51	.035	11	21	.004
No	41	8	20		14	56
Extensive chronic GVHD
Yes	16	3	19	.41	9	35	.05
No	30	3	10		7	69